{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T15:22:19Z","timestamp":1765380139228},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:p>The introduction of immunotherapy such as antiprogrammed death1 (anti-PD1) monoclonal antibodies has changed the scenario of treatment in cancer. Apart from their impressive efficacy profiles, they are better tolerated than the anticytotoxic T-lymphocyte-associated protein 4 antibodies. Dermatological adverse events such as pruritus and rash have been reported in various clinical trials. We report three cases of anti-PD1-induced bullous lichen planus (LP)-like reactions encountered in our institution. These patients developed LP-like papules and annular plaques with vesicles or crusted centres. Histology showed LP-like changes with negative immunofluorescence. Vesiculobullous lesions in patients treated with anti-PD1 therapies require a careful clinicopathological evaluation.<\/jats:p>","DOI":"10.1097\/cmr.0000000000000263","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T12:11:30Z","timestamp":1462018290000},"page":"421-424","source":"Crossref","is-referenced-by-count":39,"title":["PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases"],"prefix":"10.1097","volume":"26","author":[{"given":"Deepal V.","family":"Wakade","sequence":"first","affiliation":[{"name":"Department of Dermatology, Westmead Hospital"},{"name":"Sydney Medical School Westmead, The University of Sydney"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Carlos","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Westmead Hospital"},{"name":"Sydney Medical School Westmead, The University of Sydney"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelley J.E.","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Westmead Hospital"},{"name":"Sydney Medical School Westmead, The University of Sydney"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaun","family":"Chou","sequence":"additional","affiliation":[{"name":"Tissue Pathology and Diagnostic Oncology, Westmead Hospital, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rina","family":"Hui","sequence":"additional","affiliation":[{"name":"Sydney Medical School Westmead, The University of Sydney"},{"name":"Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Fernandez-Pe\u00f1as","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Westmead Hospital"},{"name":"Sydney Medical School Westmead, The University of Sydney"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230902","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-03-3259","article-title":"PD-L1\/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells","volume":"64","author":"Blank","year":"2004","journal-title":"Cancer Res"},{"key":"R2-20230902","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.18632\/oncotarget.2980","article-title":"PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma","volume":"6","author":"Luke","year":"2015","journal-title":"Oncotarget"},{"key":"R3-20230902","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"R4-20230902","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1517\/14740338.2015.1021774","article-title":"Safety of pembrolizumab for the treatment of melanoma","volume":"14","author":"Martin-Liberal","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"R5-20230902","doi-asserted-by":"crossref","first-page":"455.e1","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R6-20230902","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/120347540500900503","article-title":"Familial bullous lichen planus (FBLP): pedigree analysis and clinical characteristics","volume":"9","author":"Huang","year":"2005","journal-title":"J Cutan Med Surg"},{"key":"R7-20230902","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/bmj.1.6116.816-a","article-title":"Bullous lichen planus caused by labetalol","volume":"1","author":"Gange","year":"1978","journal-title":"Br Med J"},{"key":"R8-20230902","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2230.1989.tb00914.x","article-title":"Bullous lichen planus and lichen planus pemphigoides \u2013 clinico-pathological comparisons","volume":"14","author":"Gawkrodger","year":"1989","journal-title":"Clin Exp Dermatol"},{"key":"R9-20230902","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1525-1470.1993.tb00414.x","article-title":"Bullous lichen planus","volume":"10","author":"Handa","year":"1993","journal-title":"Pediatr Dermatol"},{"key":"R10-20230902","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1365-4632.2011.05113.x","article-title":"Lichen planus and lichenoid drug-induced eruption: a histological and immunohistochemical study","volume":"51","author":"Lage","year":"2012","journal-title":"Int J Dermatol"},{"key":"R11-20230902","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/archderm.142.2.166","article-title":"Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent","volume":"142","author":"Jaber","year":"2006","journal-title":"Arch Dermatol"},{"issue":"Suppl 3","key":"R12-20230902","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1111\/j.1365-4632.2007.03506.x","article-title":"Lichen planus with bullous manifestation on the lip","volume":"46","author":"van Tuyll van Serooskerken","year":"2007","journal-title":"Int J Dermatol"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008390-201608000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T03:15:30Z","timestamp":1693624530000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008390-201608000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000000263","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}